Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 6/2017

17.02.2017 | Original Article – Clinical Oncology

Elevated interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) is a poor prognostic marker in pancreatic ductal adenocarcinoma

verfasst von: Yue Zhao, Annelore Altendorf-Hofmann, Ioannis Pozios, Peter Camaj, Therese Däberitz, Xiaoyan Wang, Hanno Niess, Hendrik Seeliger, Felix Popp, Christopher Betzler, Utz Settmacher, Karl-Walter Jauch, Christiane Bruns, Thomas Knösel

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) gene from IFITs family is one gene among hundreds of IFN-stimulated genes. The potential role of IFIT3 in cancer is scarcely understood. In addition, the clinical relevance of IFIT3 is not yet known in pancreatic ductal adenocarcinoma (PDAC). We evaluated the prognostic significance of this gene in PDAC patients.

Methods

The expression of IFIT3 was analyzed in pancreatic cancer cell lines with different metastatic potential (FG and L3.6pl) and one established gemcitabine resistant cell variant-L3.6plGres. Second, we analyzed the protein expression in tissue microarrays (TMA) from specimens of 254 radically resected patients with pancreatic adenocarcinoma. The prognostic relevance of IFIT3 was evaluated by the Kaplan–Meier and Cox regression analysis.

Results

L3.6pl cells with an aggressive capacity showed a significant higher expression of IFIT3 as compared to FG cells. IFIT3 was accumulated in gemcitabine resistant cells. Overexpression of IFIT3 increased the resistance of apoptosis against gemcitabine treatment. Patients who had high expression of IFIT3 (32%) and received chemotherapy had a statistically significant reduced survival in multivariate analysis.

Conclusions

High expression of IFIT3 enhances anti-apoptotic activity and chemotherapy resistance of PDAC cells. High expression of IFIT3 was independently correlated to shorter patients’ survival and may serve as a prognostic marker.
Literatur
Zurück zum Zitat Dusch N, Weiss C, Strobel P, Kienle P, Post S, Niedergethmann M (2014) Factors predicting long-term survival following pancreatic resection for ductal adenocarcinoma of the pancreas: 40 years of experience. J Gastrointest Surg Off J Soc Surg Aliment Tract 18(4):674–681. doi:10.1007/s11605-013-2408-x CrossRef Dusch N, Weiss C, Strobel P, Kienle P, Post S, Niedergethmann M (2014) Factors predicting long-term survival following pancreatic resection for ductal adenocarcinoma of the pancreas: 40 years of experience. J Gastrointest Surg Off J Soc Surg Aliment Tract 18(4):674–681. doi:10.​1007/​s11605-013-2408-x CrossRef
Zurück zum Zitat Ferrone CR, Pieretti-Vanmarcke R, Bloom JP, Zheng H, Szymonifka J, Wargo JA, Thayer SP, Lauwers GY, Deshpande V, Mino-Kenudson M, Fernandez-del Castillo C, Lillemoe KD, Warshaw AL (2012) Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery 152(3 Suppl 1):S43–49. doi:10.1016/j.surg.2012.05.020 CrossRefPubMedPubMedCentral Ferrone CR, Pieretti-Vanmarcke R, Bloom JP, Zheng H, Szymonifka J, Wargo JA, Thayer SP, Lauwers GY, Deshpande V, Mino-Kenudson M, Fernandez-del Castillo C, Lillemoe KD, Warshaw AL (2012) Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery 152(3 Suppl 1):S43–49. doi:10.​1016/​j.​surg.​2012.​05.​020 CrossRefPubMedPubMedCentral
Zurück zum Zitat Mayo SC, Austin DF, Sheppard BC, Mori M, Shipley DK, Billingsley KG (2010) Adjuvant therapy and survival after resection of pancreatic adenocarcinoma: a population-based analysis. Cancer 116(12):2932–2940. doi:10.1002/cncr.25082 CrossRefPubMed Mayo SC, Austin DF, Sheppard BC, Mori M, Shipley DK, Billingsley KG (2010) Adjuvant therapy and survival after resection of pancreatic adenocarcinoma: a population-based analysis. Cancer 116(12):2932–2940. doi:10.​1002/​cncr.​25082 CrossRefPubMed
Zurück zum Zitat Michael M, Moore M (1997) Clinical experience with gemcitabine in pancreatic carcinoma. Oncology (Williston Park) 11(11):1615–1622; (discussion 1622, 1625-1617) Michael M, Moore M (1997) Clinical experience with gemcitabine in pancreatic carcinoma. Oncology (Williston Park) 11(11):1615–1622; (discussion 1622, 1625-1617)
Zurück zum Zitat Niess H, Camaj P, Mair R, Renner A, Zhao Y, Jackel C, Nelson PJ, Jauch KW, Bruns CJ (2015a) Overexpression of IFN-induced protein with tetratricopeptide repeats 3 (IFIT3) in pancreatic cancer: cellular “pseudoinflammation” contributing to an aggressive phenotype. Oncotarget 6(5):3306–3318CrossRefPubMed Niess H, Camaj P, Mair R, Renner A, Zhao Y, Jackel C, Nelson PJ, Jauch KW, Bruns CJ (2015a) Overexpression of IFN-induced protein with tetratricopeptide repeats 3 (IFIT3) in pancreatic cancer: cellular “pseudoinflammation” contributing to an aggressive phenotype. Oncotarget 6(5):3306–3318CrossRefPubMed
Zurück zum Zitat Niess H, Camaj P, Renner A, Ischenko I, Zhao Y, Krebs S, Mysliwietz J, Jackel C, Nelson PJ, Blum H, Jauch KW, Ellwart JW, Bruns CJ (2015b) Side population cells of pancreatic cancer show characteristics of cancer stem cells responsible for resistance and metastasis. Targeted oncology 10(2):215–227. doi:10.1007/s11523-014-0323-z CrossRefPubMed Niess H, Camaj P, Renner A, Ischenko I, Zhao Y, Krebs S, Mysliwietz J, Jackel C, Nelson PJ, Blum H, Jauch KW, Ellwart JW, Bruns CJ (2015b) Side population cells of pancreatic cancer show characteristics of cancer stem cells responsible for resistance and metastasis. Targeted oncology 10(2):215–227. doi:10.​1007/​s11523-014-0323-z CrossRefPubMed
Zurück zum Zitat Sobin LH, Gospodarowicz MK, Wittekind C, International Union against Cancer. (2010) TNM classification of malignant tumours. 7th edn. Wiley-Blackwell, Chichester Sobin LH, Gospodarowicz MK, Wittekind C, International Union against Cancer. (2010) TNM classification of malignant tumours. 7th edn. Wiley-Blackwell, Chichester
Zurück zum Zitat Stratford JK, Bentrem DJ, Anderson JM, Fan C, Volmar KA, Marron JS, Routh ED, Caskey LS, Samuel JC, Der CJ, Thorne LB, Calvo BF, Kim HJ, Talamonti MS, Iacobuzio-Donahue CA, Hollingsworth MA, Perou CM, Yeh JJ (2010) A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma. PLoS Med 7 (7):e1000307. doi:10.1371/journal.pmed.1000307 CrossRefPubMedPubMedCentral Stratford JK, Bentrem DJ, Anderson JM, Fan C, Volmar KA, Marron JS, Routh ED, Caskey LS, Samuel JC, Der CJ, Thorne LB, Calvo BF, Kim HJ, Talamonti MS, Iacobuzio-Donahue CA, Hollingsworth MA, Perou CM, Yeh JJ (2010) A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma. PLoS Med 7 (7):e1000307. doi:10.​1371/​journal.​pmed.​1000307 CrossRefPubMedPubMedCentral
Zurück zum Zitat Varadhachary GR, Wolff RA, Crane CH, Sun CC, Lee JE, Pisters PW, Vauthey JN, Abdalla E, Wang H, Staerkel GA, Lee JH, Ross WA, Tamm EP, Bhosale PR, Krishnan S, Das P, Ho L, Xiong H, Abbruzzese JL, Evans DB (2008) Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol Off J Am Soc Clin Oncol 26(21):3487–3495. doi:10.1200/JCO.2007.15.8642 CrossRef Varadhachary GR, Wolff RA, Crane CH, Sun CC, Lee JE, Pisters PW, Vauthey JN, Abdalla E, Wang H, Staerkel GA, Lee JH, Ross WA, Tamm EP, Bhosale PR, Krishnan S, Das P, Ho L, Xiong H, Abbruzzese JL, Evans DB (2008) Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol Off J Am Soc Clin Oncol 26(21):3487–3495. doi:10.​1200/​JCO.​2007.​15.​8642 CrossRef
Zurück zum Zitat Wacher C, Muller M, Hofer MJ, Getts DR, Zabaras R, Ousman SS, Terenzi F, Sen GC, King NJ, Campbell IL (2007) Coordinated regulation and widespread cellular expression of interferon-stimulated genes (ISG) ISG-49, ISG-54, and ISG-56 in the central nervous system after infection with distinct viruses. J Virol 81(2):860–871. doi:10.1128/JVI.01167-06 CrossRefPubMed Wacher C, Muller M, Hofer MJ, Getts DR, Zabaras R, Ousman SS, Terenzi F, Sen GC, King NJ, Campbell IL (2007) Coordinated regulation and widespread cellular expression of interferon-stimulated genes (ISG) ISG-49, ISG-54, and ISG-56 in the central nervous system after infection with distinct viruses. J Virol 81(2):860–871. doi:10.​1128/​JVI.​01167-06 CrossRefPubMed
Metadaten
Titel
Elevated interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) is a poor prognostic marker in pancreatic ductal adenocarcinoma
verfasst von
Yue Zhao
Annelore Altendorf-Hofmann
Ioannis Pozios
Peter Camaj
Therese Däberitz
Xiaoyan Wang
Hanno Niess
Hendrik Seeliger
Felix Popp
Christopher Betzler
Utz Settmacher
Karl-Walter Jauch
Christiane Bruns
Thomas Knösel
Publikationsdatum
17.02.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 6/2017
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-017-2351-4

Weitere Artikel der Ausgabe 6/2017

Journal of Cancer Research and Clinical Oncology 6/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.